Advertisement: TTP Killer 50
18 April, 2019 - 23:50 By Jamie Quested

Alchemab Therapeutics

Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires. 

Last year the company unveiled a new CEO in a bid to drive quickfire transatlantic growth. Douglas Treco will be based in Boston and succeeds Alex Leech.

Alchemab raised $82 million in a Series A financing in April 2021  led by RA Capital and was joined by Lightstone Ventures, DHVC, and DCVC Bio. The company’s 2019 seed round was led by SV Health Investors and the Dementia Discovery Fund.

Job opportunities at Alchemab

Newsletter Subscription

Stay informed of the latest news and features